楊明 伏飛達(dá) 朱曉燕
[摘要] 目的 探討突發(fā)性耳聾患者血清可溶性血管細(xì)胞黏附分子-1(sVCAM-1)的表達(dá)水平及臨床意義。 方法 選擇2016年1月~2017年6月南京市中西醫(yī)結(jié)合醫(yī)院收治的97例突發(fā)性耳聾患者作為病例組,并于同期隨機(jī)選取60名健康體檢者為對(duì)照組,采用酶聯(lián)免疫吸附法測(cè)定兩組血清sVCAM-1水平,并分析其與患者人口學(xué)資料的關(guān)系以及其對(duì)突發(fā)性耳聾的診斷價(jià)值。 結(jié)果 病例組患者血清sVCAM-1水平高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P < 0.05)?!?5歲患者血清sVCAM-1水平高于<45歲者,聽力損失嚴(yán)重患者血清sVCAM-1水平更高,全聾型患者血清sVCAM-1水平高于其他分型,有上呼吸道感染和心腦血管合并癥患者血清sVCAM-1水平更高,差異均有統(tǒng)計(jì)學(xué)意義(P < 0.05)。sVCAM-1診斷突發(fā)性耳聾的ROC曲線下面積為0.904(95%CI:0.841~0.967),靈敏度為76.5%,特異度為91.8%,此時(shí)sVCAM-1的最佳截?cái)嘀禐?79.23 ng/mL。 結(jié)論 突發(fā)性耳聾患者血清sVCAM-1水平明顯升高,其與年齡、聽力下降程度、聽力曲線、上呼吸道感染、心腦血管合并癥密切相關(guān),早期檢測(cè)可有效預(yù)測(cè)突發(fā)性耳聾的發(fā)生。
[關(guān)鍵詞] 突發(fā)性耳聾;可溶性血管細(xì)胞黏附分子-1;臨床意義
[中圖分類號(hào)] R764.43 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1673-7210(2018)05(c)-0119-04
Changes and significance of serum sVCAM-1 level in patients with sudden deafness
YANG Ming FU Feida ZHU Xiaoyan
Department of ENT, Nanjing Integrated Traditional Chinese and Western Medicine Hospital, Jiangsu Province, Nanjing 210000, China
[Abstract] Objective To explore the expression of serum soluble vascular cell adhesion molecule-1 (sVCAM-1) and its clinical significance. Methods A total of 97 patients with sudden deafness admitted to Nanjing Integrated Traditional Chinese and Western Medicine Hospital from January 2016 to June 2017 were selected as the case group, 60 healthy subjects were randomly selected as the control group at the same period. The serum sVCAM-1 level in the two groups was measured by the enzyme-linked immunosorbent assay, in addition, the relationship between sVCAM-1 with patients' demographic data and the diagnostic value of sVCAM-1 for sudden deafness were analyzed. Results The serum sVCAM-1 level in the case group was higher than that of control group, with statistically significant difference (P < 0.05). The sVCAM-1 level of patients at the age≥45 was higher than the age<45, and sVCAM-1 level in patients with severe hearing loss was more higher, and sVCAM-1 level in patients with total deafness type was more higher than those in other types, sVCAM-1 level of patients with upper respiratory tract infection and cardiovascular complications were more higher, with statistically significant differences (P < 0.05). The ROC area of sVCAM-1 in the diagnosis of sudden deafness was 0.904 (95%CI:0.841-0.967), the sensitivity was 76.5% and the specificity was 91.8%, the best truncation value of sVCAM-1 at this time was 579.23 ng/mL. Conclusion The serum sVCAM-1 in patients with sudden deafness is significantly elevated, which is closely related to age, hearing loss, hearing curve, upper respiratory tract infection and cerebrovascular complications. Early detection can effectively predict the occurrence of sudden deafness.
[Key words] Sudden deafness; Soluble vascular cell adhesion molecule-1; Clinical significance
耳聾是臨床耳鼻喉科常見的急癥,是指突然發(fā)生,短時(shí)間內(nèi)(幾分鐘、幾小時(shí)或者3 d以內(nèi))出現(xiàn)原因不明的感音神經(jīng)性聽力損失,并且至少兩個(gè)相連的頻率聽力下降超過20 dB,常伴有不同程度的耳鳴、眩暈等臨床癥狀[1-2]。流行病學(xué)調(diào)查顯示[3],突發(fā)性耳聾人群發(fā)病率在5萬(wàn)~20/10萬(wàn)之間,隨著人們生活節(jié)奏的加快以及工作生活壓力的增大,其發(fā)病率逐漸升高。研究發(fā)現(xiàn)[4],約有30%~60%的突發(fā)性耳聾患者因治療不及時(shí)而損傷前庭,進(jìn)一步加重聽力損傷,影響患者預(yù)后。早發(fā)現(xiàn)、早診斷、早治療是有效緩解突發(fā)性聽力耳聾癥狀,改善患者預(yù)后的重要措施。研究證實(shí)[5],免疫異常、病毒感染、內(nèi)耳循環(huán)障礙等是導(dǎo)致突發(fā)性耳聾的重要因素,而內(nèi)耳循環(huán)障礙是主要的發(fā)病機(jī)制之一??扇苄匝芗?xì)胞黏附分子-1(solube vascular cell adhesion molecule-1,sVCAM-1)是由血管內(nèi)皮細(xì)胞表面的黏附分子脫落后進(jìn)入血液所形成的跨膜糖蛋白分子,研究顯示[6-7],sVCAM-1參與了細(xì)胞的信號(hào)轉(zhuǎn)導(dǎo)、活化過程,在糖尿病性血管病變、動(dòng)脈粥樣硬化、創(chuàng)傷等疾病的發(fā)生和發(fā)展過程中發(fā)揮重要作用。關(guān)于sVCAM-1在突發(fā)性耳聾發(fā)病過程中的作用,目前相關(guān)報(bào)道較少。本研究通過檢測(cè)突發(fā)性耳聾患者血清sVCAM-1水平,旨在探討其與突發(fā)性耳聾患者高危因素的關(guān)系及其在突發(fā)性耳聾診斷中的價(jià)值?,F(xiàn)報(bào)道如下:
1 資料與方法
1.1 一般資料
選擇2016年1月~2017年6月南京市中西醫(yī)結(jié)合醫(yī)院(以下簡(jiǎn)稱“我院”)耳鼻喉科收治的97例突發(fā)性耳聾患者為病例組,所有患者均接受過純音測(cè)聽、聲導(dǎo)抗檢查,且符合2006年中華耳鼻喉科學(xué)會(huì)制訂的《突發(fā)性聾的診斷和治療指南》中關(guān)于突發(fā)性耳聾的診斷標(biāo)準(zhǔn)[8]。排除標(biāo)準(zhǔn):①妊娠期以及哺乳期的婦女;②心臟功能不全者;③肝、腎功能障礙者;④中樞神經(jīng)系統(tǒng)、外傷史、中耳和外耳疾病等原因所致的耳聾性疾病;⑤顱內(nèi)病變?nèi)缏犐窠?jīng)瘤、大前庭水管綜合征等可能引起聽力下降的疾病。其中男55例,女42例;年齡19~62歲,平均(45.1±7.6)歲;發(fā)病至就診時(shí)間為8 h~12 d,平均(5.2±1.7)d;根據(jù)WHO聽力損失分級(jí)標(biāo)準(zhǔn)[9]:輕度22例,中度27例,重度28例,極重度20例;根據(jù)聽力曲線將患者分型[10]:低中頻下降型19例,中高頻下降型34例,平坦下降型25例,全聾型19例;上呼吸道感染29例,心腦血管合并癥17例,其他51例。并于同期隨機(jī)選取60名健康體檢者為對(duì)照組,其中男37例,女23例;年齡23~75歲,平均(46.5±6.8)歲。兩組性別、年齡比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P > 0.05),具有可比性。本研究經(jīng)我院醫(yī)學(xué)倫理委員會(huì)審批,患者對(duì)本研究知情同意并簽署知情同意書。
1.2 方法
病例組患者于入院后次日清晨空腹抽取肘靜脈血4 mL,并以同一方法抽取對(duì)照組空腹肘靜脈血4 mL,以3000 r/min的速度離心10 min后留取上清液,置于-70℃環(huán)境下保存,留待檢測(cè)。采用酶聯(lián)免疫吸附法測(cè)定兩組血清sVCAM-1水平。試劑盒由上海斯信生物科技有限公司提供,嚴(yán)格按照試劑盒上的說(shuō)明進(jìn)行相關(guān)操作。
1.3 統(tǒng)計(jì)學(xué)方法
采用SPSS 19.0對(duì)所得數(shù)據(jù)進(jìn)行統(tǒng)計(jì)學(xué)分析,計(jì)量資料采用均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,兩組獨(dú)立樣本比較采用t檢驗(yàn),多組獨(dú)立樣本比較采用方差分析,兩兩比較采用LSD-t檢驗(yàn),sVCAM-1對(duì)突發(fā)性耳聾的診斷標(biāo)準(zhǔn)采用ROC曲線評(píng)定,以P < 0.05為差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1 兩組血清sVCAM-1水平比較
病例組血清sVCAM-1水平高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P < 0.05)。
2.2 病例組人口學(xué)資料與血清sVCAM-1的關(guān)系
不同年齡、聽力損失程度、聽力曲線分型的突發(fā)性耳聾患者血清sVCAM-1水平比較,差異有統(tǒng)計(jì)學(xué)意義(P < 0.05)?!?5歲患者血清sVCAM-1水平高于<45歲者,聽力損失越嚴(yán)重的患者血清sVCAM-1水平越高,全聾型突發(fā)性耳聾患者血清sVCAM-1水平高于其他聽力曲線分型;有上呼吸道感染和心腦血管合并癥的突發(fā)性耳聾患者血清sVCAM-1水平更高,差異有統(tǒng)計(jì)學(xué)意義(P < 0.05)。見表2。
2.3 sVCAM-1對(duì)突發(fā)性耳聾的診斷價(jià)值
sVCAM-1診斷突發(fā)性耳聾的ROC曲線下面積為0.904(95%CI:0.841~0.967),靈敏度為76.5%,特異度為91.8%,此時(shí)的最佳截?cái)嘀禐?79.23 ng/ mL。見圖1。
3 討論
突發(fā)性耳聾臨床表現(xiàn)主要有單側(cè)聽力下降,并伴有不同程度的耳堵塞感、耳鳴、眩暈、惡心嘔吐等,嚴(yán)重影響患者的日常生活。有研究顯示[11-12],年齡、上呼吸道感染、心腦血管合并癥等多種因素是突發(fā)性耳聾發(fā)生的高危因素,年齡越大的人群,其家庭、工作和社會(huì)壓力相對(duì)較大,身體應(yīng)激反應(yīng)大、心理狀況不佳,因此容易導(dǎo)致血管痙攣而使耳局部血液供應(yīng)不足,最終導(dǎo)致突發(fā)性耳聾;合并有上呼吸道感染的人群,機(jī)體易出現(xiàn)炎性反應(yīng),導(dǎo)致循環(huán)功能障礙而引發(fā)突發(fā)性耳聾;心腦血管合并癥易損傷迷路動(dòng)脈,進(jìn)而導(dǎo)致內(nèi)耳缺血而發(fā)生突發(fā)性耳聾。
關(guān)于突發(fā)性耳聾的發(fā)病機(jī)制,目前學(xué)術(shù)界尚無(wú)統(tǒng)一定論,而臨床治療也無(wú)特效藥,只能采用對(duì)癥支持治療改善患者的癥狀。因此,探討突發(fā)性耳聾的發(fā)病機(jī)制并尋找特異性的標(biāo)志物早期輔助診斷突發(fā)性耳聾,對(duì)提高患者的臨床治療效果、改善預(yù)后有重要意義。研究證實(shí)[13],病毒感染、內(nèi)耳循環(huán)障礙、免疫異常等是突發(fā)性耳聾常見的發(fā)病機(jī)制,其中內(nèi)皮細(xì)胞功能障礙所致的內(nèi)耳微循環(huán)紊亂是突發(fā)性耳聾的主要發(fā)病機(jī)制。黏附分子是由細(xì)胞產(chǎn)生的具有多種生物活性的跨膜糖蛋白,主要介導(dǎo)細(xì)胞的信號(hào)轉(zhuǎn)導(dǎo)和活化、細(xì)胞的生長(zhǎng)與分化、血栓形成、炎性反應(yīng)、創(chuàng)傷愈合等重要的病理生理過程,研究證實(shí)[14],黏附分子是反映內(nèi)皮細(xì)胞損傷的重要標(biāo)志。sVCAM-1是血管細(xì)胞表達(dá)的主要黏附因子,是由血管細(xì)胞黏附分子-1從血管內(nèi)皮細(xì)胞脫落后進(jìn)入血液所形成,與血清中細(xì)胞黏附分子-1水平呈正相關(guān)關(guān)系[2]。已有報(bào)道顯示[15-16],sVCAM-1通過介導(dǎo)嗜酸性粒細(xì)胞、淋巴細(xì)胞以及單核細(xì)胞等而黏附在血管壁上,并穿過血管內(nèi)皮而發(fā)揮炎癥損傷反應(yīng),進(jìn)而導(dǎo)致動(dòng)脈粥樣硬化。此外,sVCAM-1還介導(dǎo)了合并糖尿病的基線冠脈綜合征、急性腦梗死等炎癥性疾病。
關(guān)于sVCAM-1與突發(fā)性耳聾關(guān)系的報(bào)道相對(duì)較少,本研究通過檢測(cè)其在突發(fā)性耳聾患者血清中的表達(dá)水平,旨在探討其對(duì)突發(fā)性耳聾的診斷價(jià)值。結(jié)果顯示,病例組患者血清sVCAM-1水平高于對(duì)照組,提示sVCAM-1可能參與了突發(fā)性耳聾內(nèi)皮功能障礙,與有關(guān)研究結(jié)果一致[17]。此外,結(jié)果顯示,≥45歲突發(fā)性耳聾患者血清sVCAM-1水平更高,可能是因?yàn)槟挲g偏大患者更易發(fā)生動(dòng)脈粥樣硬化,而動(dòng)脈粥樣硬化是一個(gè)慢性炎癥過程,細(xì)胞黏附分子在炎性反應(yīng)過程中發(fā)揮重要作用。此外,聽力損失越嚴(yán)重的患者和音頻損失越嚴(yán)重的患者,血清sVCAM-1水平越高,提示sVCAM-1可作為評(píng)估突發(fā)性耳聾患者病情嚴(yán)重程度的重要指標(biāo),臨床有重要參考價(jià)值。此外,研究表明[18],有上呼吸道感染的突發(fā)性耳聾患者血清sVCAM-1水平更高,可能是因?yàn)樯虾粑栏腥緦?dǎo)致的炎性反應(yīng)可使血管細(xì)胞黏附分子-1表達(dá)水平升高,進(jìn)而sVCAM-1的分泌量增加,進(jìn)一步刺激炎性反應(yīng)局部淋巴細(xì)胞的浸潤(rùn),此時(shí)炎性因子在血管細(xì)胞黏附分子的調(diào)節(jié)下穿過血管到達(dá)炎癥部位,這一過程中,血管的內(nèi)皮細(xì)胞損傷嚴(yán)重,導(dǎo)致血管出現(xiàn)嚴(yán)重的炎性反應(yīng)而形成循環(huán)功能障礙[19]。內(nèi)耳的血液供應(yīng)主要是小腦前下動(dòng)脈分出的迷路動(dòng)脈,其他的代償動(dòng)脈較少,當(dāng)內(nèi)耳出現(xiàn)持續(xù)性缺血時(shí)耳蝸電位會(huì)消失,如果缺血持續(xù)時(shí)間超過30 min,即使血液供應(yīng)得到恢復(fù)也很難使耳蝸電位恢復(fù),因此,當(dāng)心腦血管并發(fā)癥累及迷路動(dòng)脈,極易導(dǎo)致內(nèi)耳缺血缺氧而引發(fā)突發(fā)性耳聾[20-21]。本研究中,有心腦血管合并癥的突發(fā)性耳聾患者血清sVCAM-1水平更高。上述結(jié)果提示,sVCAM-1與突發(fā)性耳聾的高危因素密切相關(guān),提示sVCAM-1可能參與了突發(fā)性耳聾的發(fā)生發(fā)展過程,并可預(yù)測(cè)突發(fā)性耳聾病情嚴(yán)重程度。進(jìn)一步檢驗(yàn)sVCAM-1對(duì)突發(fā)性耳聾的診斷價(jià)值,結(jié)果顯示,sVCAM-1診斷突發(fā)性耳聾的ROC曲線下面積為0.904,此時(shí)的靈敏度、特異度分別為76.5%、91.8%,最佳截?cái)嘀禐?79.23 ng/mL,提示早期檢測(cè)sVCAM-1可作為診斷突發(fā)性耳聾的重要指標(biāo)。
綜上所述,突發(fā)性耳聾患者血清中sVCAM-1表達(dá)水平明顯升高,并且與突發(fā)性耳聾高危因素密切相關(guān),可能參與了突發(fā)性耳聾的發(fā)生過程,早期檢測(cè)可作為輔助診斷突發(fā)性耳聾的重要指標(biāo),對(duì)臨床有重要參考價(jià)值。
[參考文獻(xiàn)]
[1] Bulgurcu S,Dikilita?觭 B,Arslan IB,et al. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Pediatric Patients with IdiopathicSudden Hearing Loss [J]. J Int Adv Otol,2017,13(2):217-220.
[2] 許航宇,舒海榮,宋建新.老年突發(fā)性耳聾患者血清可溶性血管細(xì)胞黏附分子-1水平及其影響因素[J].中國(guó)老年學(xué)雜志,2017,37(2):452-453.
[3] Schreiber BE,Agrup C,Haskard DO,et al. Sudden sensorineural hearing loss [J]. Lancet,2010,375(9721):1203-1211.
[4] Ito T,Li X,Kurima K,et al. Slc26a4-insufficiency causes fluctuating hearing loss and striavascularis dysfunction [J]. Neurobiol Dis,2014,66(2):53-65.
[5] Shih CP,Chou YC,Chen HC,et al. Analysis of caloric test responses in sudden hearing loss [J]. Ear Nose Throat J,2017, 96(2):59-64.
[6] 潘凌云,朱貴月,馬曉靜,等.老年急性冠脈綜合征患者血清sICAM-1、sVCAM-1變化及影響因素和瑞舒伐他汀的干預(yù)作用[J].中國(guó)老年學(xué)雜志,2011,31(1):38-40.
[7] Shim BJ,Lee DH,Youn HJ. Increased soluble vascular adhesion molecule-1 concentration is associated with impaired coronary flow reserve in cardiac syndrome X [J]. Heart Vessels,2014,29(6):723-731.
[8] 中華耳鼻咽喉頭頸外科雜志編輯委員會(huì),中華醫(yī)學(xué)會(huì)耳鼻咽喉頭頸外科學(xué)分會(huì).突發(fā)性聾的診斷和治療指南(2005年,濟(jì)南)[J].中華耳鼻咽喉頭頸外科雜志,2006,41(8):569.
[9] 汪吉寶,段家德,陳海華,等.聽神經(jīng)病106例聽力學(xué)分析[J].中華耳鼻咽喉頭頸外科雜志,2008,43(5):347-350.
[10] 陳黎黎,江黎珠,胡國(guó)平.突發(fā)性耳聾預(yù)后相關(guān)影響因素的分析[J].第三軍醫(yī)大學(xué)學(xué)報(bào),2015,37(11):1141-1145.
[11] Min SK,Shin JH,Chang MY,et al. Impact of control of blood glucose level during treatment of sudden deafness in diabetics:relationship with prognosis [J]. Eur Arch Otorhinolaryngol,2017,274(3):1339-1343.
[12] Liebau A,Pogorzelski O,Salt AN,et al. HearingChanges After Intratympanically Applied Steroids for Primary Therapy ofSudden Hearing Loss:A Meta-analysis Using Mathematical Simulations of Drug Delivery Protocols [J]. Otol Neurotol,2017,38(1):19-30.
[13] Kim SH,Jung AR,Kim SI,et al. Refractory Granulomatosis with Polyangiitis Presenting as Facial Paralysis and Bilateral?Sudden Deafness [J]. J Audiol Otol,2016,20(1):55-58.
[14] Cochran DB,Gray LN,Anderson KW,et al. Degradable poly(apigenin) polymer inhibits tumor cell adhesion to vascular endothelial cells [J]. J Biomed Mater Res B Appl Biomater,2016,104(7):1438-1447.
[15] Kocijancic M,Cubranic Z,Vujicic B,et al. Solubleintracellularadhesionmolecule-1 and omentin-1 as potential biomarkers of subclinicalatherosclerosisin hemodialysis patients [J]. Int Urol Nephrol,2016,48(7):1145-1154.
[16] Lisowska A,Siergiejko E,Tycinska A,et al. sVCAM-1concentration and carotid IMT values in patients with acute myocardial infarction-Atherosclerotic markers of the presence,progress and prognosis [J]. Adv Med Sci,2015,60(1):101-106.
[17] Quaranta N,Ramunni A,Brescia P,et al. Solubleintercellularadhesionmolecule 1 and soluble vascular cell adhesion molecule 1 insudden hearing loss [J]. Otol Neurotol,2008,29(4):470-474.
[18] Atay G,Kayahan B,cinar B?觭,et al. Prognostic Factors in Sudden Sensorineural Hearing Loss [J]. Balkan Med J,2016, 33(1):87-93.
[19] Orndorff RL,Hong N,Yu K,et al. NOX2 in lung inflammation:quantum dot based in situ imaging of NOX2-mediated expression of vascular cell adhesion molecule-1 [J]. Am J Physiol Lung Cell Mol Physiol,2014,306(3):L260-L268.
[20] Kim SH,Kim SJ,Im H,et al. A Trend in Sudden Sensorineural Hearing Loss:Data from a Population-Based Study [J]. Audiol Neurootol,2018,22(6):311-316.
[21] Kim JY,Hong JY,Kim DK. Association of Sudden Sensor ineural Hearing Loss With Risk of Cardiocerebrovascular Disease:A Study Using Data From the Korea National Health Insurance Service [J]. JAMA Otolaryngol Head Neck Surg,2018,144(2):129-135.
(收稿日期:2017-10-21本文編輯:王 娟)